0001209191-20-062624.txt : 20201209 0001209191-20-062624.hdr.sgml : 20201209 20201209195443 ACCESSION NUMBER: 0001209191-20-062624 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20201207 FILED AS OF DATE: 20201209 DATE AS OF CHANGE: 20201209 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Rhodes Jason P CENTRAL INDEX KEY: 0001577014 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38596 FILM NUMBER: 201379107 MAIL ADDRESS: STREET 1: C/O EPIZYME, INC. STREET 2: 400 TECHNOLOGY SQUARE, 4TH FLOOR CITY: CAMBRIDGE STATE: MA ZIP: 02139 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Replimune Group, Inc. CENTRAL INDEX KEY: 0001737953 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 822082553 STATE OF INCORPORATION: DE FISCAL YEAR END: 0331 BUSINESS ADDRESS: STREET 1: 500 UNICORN PARK CITY: WOBURN STATE: MA ZIP: 01801 BUSINESS PHONE: (781) 222-9600 MAIL ADDRESS: STREET 1: 500 UNICORN PARK CITY: WOBURN STATE: MA ZIP: 01801 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2020-12-07 0 0001737953 Replimune Group, Inc. REPL 0001577014 Rhodes Jason P 18 COMMERCE WAY WOBURN MA 01801 1 0 0 0 Common Stock 2020-12-07 4 S 0 8636 45.46 D 2477660 I See Footnote Common Stock 2020-12-07 4 S 0 23174 45.97 D 2454486 I See Footnote Common Stock 2020-12-07 4 S 0 1222 46.91 D 2453264 I See Footnote Common Stock 2020-12-07 4 S 0 2962 45.45 D 1097038 I See Footnote Common Stock 2020-12-07 4 S 0 26713 46.06 D 1070325 I See Footnote Common Stock 2020-12-07 4 S 0 2322 46.93 D 1068003 I See Footnote Common Stock 2020-12-07 4 S 0 748 45.46 D 37822 I See Footnote Common Stock 2020-12-07 4 S 0 2007 45.97 D 35815 I See Footnote Common Stock 2020-12-07 4 S 0 106 46.91 D 35709 I See Footnote Common Stock 2020-12-08 4 S 0 7001 46.02 D 2446263 I See Footnote Common Stock 2020-12-08 4 S 0 33133 46.94 D 2413130 I See Footnote Common Stock 2020-12-08 4 S 0 19620 46.14 D 1048383 I See Footnote Common Stock 2020-12-08 4 S 0 45027 46.89 D 1003356 I See Footnote Common Stock 2020-12-08 4 S 0 606 46.02 D 35103 I See Footnote Common Stock 2020-12-08 4 S 0 2869 46.94 D 32234 I See Footnote Common Stock 2020-12-09 4 S 0 1745 42.51 D 2411385 I See Footnote Common Stock 2020-12-09 4 S 0 17883 43.36 D 2393502 I See Footnote Common Stock 2020-12-09 4 S 0 7330 44.69 D 2386172 I See Footnote Common Stock 2020-12-09 4 S 0 1747 45.32 D 2384425 I See Footnote Common Stock 2020-12-09 4 S 0 603 42.51 D 1002753 I See Footnote Common Stock 2020-12-09 4 S 0 6183 43.36 D 996570 I See Footnote Common Stock 2020-12-09 4 S 0 2535 44.69 D 994035 I See Footnote Common Stock 2020-12-09 4 S 0 604 45.32 D 993431 I See Footnote Common Stock 2020-12-09 4 S 0 100 46.47 D 993331 I See Footnote Common Stock 2020-12-09 4 S 0 151 42.51 D 32083 I See Footnote Common Stock 2020-12-09 4 S 0 1549 43.36 D 30534 I See Footnote Common Stock 2020-12-09 4 S 0 635 44.69 D 29899 I See Footnote Common Stock 2020-12-09 4 S 0 151 45.32 D 29748 I See Footnote Shares were sold pursuant to a Rule 10b5-1 trading plan. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.71 to $45.708 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (5), (6), (7), (9), (10), (12), (13), (14), (15), (16) and (17). The shares reported herein give effect to the pro rata distribution of shares by Atlas Venture Fund X, L.P. ("Atlas Venture Fund X") for no additional consideration to its limited and general partner, Atlas Venture Associates X, L.P. ("AVA X LP") subsequent to the Reporting Person's last Section 16 filing reporting ownership of the Issuer's Common Stock. As the distributions of such shares constituted only a change in the form of the Reporting Person's indirect ownership in such shares, the Reporting Person was not required to report these distributions pursuant to Section 16. The shares are held directly by Atlas Venture Fund X. The general partner of Atlas Venture Fund X is AVA X LP. Atlas Venture Associates X, LLC ("AVA X LLC") is the general partner of AVA X LP. The Reporting Person is a member of AVA X LLC and disclaims beneficial ownership of such securities held by Atlas Venture Fund X, except to the extent of his pecuniary interest therein, if any. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.71 to $46.67 inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $46.71 to $47.19 inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.71 to $45.70 inclusive. The shares are held directly by Atlas Venture Opportunity Fund I, L.P. ("Atlas Venture Opportunity Fund I"). The general partner of Atlas Venture Opportunity Fund I is Atlas Venture Associates Opportunity I, L.P. ("AVAO I LP"). Atlas Venture Associates Opportunity I, LLC ("AVAO I LLC") is the general partner of AVAO I LP. The Reporting Person is a member of AVAO I LLC and disclaims beneficial ownership of such securities held by Atlas Venture Opportunity Fund I, except to the extent of his pecuniary interest therein, if any. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.71 to $46.68 inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $46.71 to $47.23 inclusive. The shares are held directly by AVA X LP. The Reporting Person is a member of AVA X LLC and disclaims beneficial ownership of such securities held by AVA X LP, except to the extent of his pecuniary interest therein, if any. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.52 to $46.42 inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $46.55 to $47.45 inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.95 to $42.91 inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.97 to $43.94 inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.07 to $45.06 inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.07 to $45.96 inclusive. /s/ Ommer Chohan, Attorney-in-Fact 2020-12-09